gyki 52466 has been researched along with Nerve Degeneration in 11 studies
GYKI 52466: an AMPA (non-NMDA) receptor antagonist; structure given in first source
Nerve Degeneration: Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Kainic acid (KA) treatment induced neuronal death and apoptosis in murine cerebellar granule cells (CGNs) cultures from both wild-type and knockout p21(-/-) mice." | 1.32 | p21(WAF1/Cip1) is not involved in kainic acid-induced apoptosis in murine cerebellar granule cells. ( Camins, A; Canudas, AM; Folch, J; Jiménez, A; Jordà, EG; Pallàs, M; Rimbau, V; Verdaguer, E, 2004) |
| "There was a commensurate reduction in seizure-related neuronal loss in the limbic regions of the brain." | 1.31 | In vivo, the direct and seizure-induced neuronal cytotoxicity of kainate and AMPA is modified by the non-competitive antagonist, GYKI 52466. ( Lees, GJ; Leong, W, 2001) |
| " In contrast, neither QA up to 5 mM nor trans-ACPD had a significant toxic effect in either KCl group." | 1.30 | NMDA and non-NMDA receptor-mediated excitotoxicity are potentiated in cultured striatal neurons by prior chronic depolarization. ( Chen, Q; Reiner, A; Surmeier, DJ, 1999) |
| "GYKI 52466 is a benzodiazepine molecule that has muscle relaxant and anticonvulsant properties not attributable to a gamma-aminobutyric acid receptor-mediated mechanism." | 1.29 | A benzodiazepine recognition site associated with the non-NMDA glutamate receptor. ( Olney, JW; Price, MT; Yamada, KA; Zorumski, CF, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (45.45) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Elger, B | 1 |
| Huth, A | 1 |
| Neuhaus, R | 1 |
| Ottow, E | 1 |
| Schneider, H | 1 |
| Seilheimer, B | 1 |
| Turski, L | 1 |
| O'Hearn, E | 1 |
| Molliver, ME | 1 |
| Caccamo, D | 1 |
| Campisi, A | 1 |
| Currò, M | 1 |
| Li Volti, G | 1 |
| Vanella, A | 1 |
| Ientile, R | 1 |
| Verdaguer, E | 1 |
| Jordà, EG | 1 |
| Canudas, AM | 1 |
| Jiménez, A | 1 |
| Folch, J | 1 |
| Rimbau, V | 1 |
| Pallàs, M | 1 |
| Camins, A | 1 |
| Gressens, P | 1 |
| Spedding, M | 1 |
| Gigler, G | 1 |
| Kertesz, S | 1 |
| Villa, P | 1 |
| Medja, F | 1 |
| Williamson, T | 1 |
| Kapus, G | 1 |
| Levay, G | 1 |
| Szenasi, G | 1 |
| Barkoczy, J | 1 |
| Harsing, LG | 1 |
| Rothstein, JD | 1 |
| Bristol, LA | 1 |
| Hosler, B | 1 |
| Brown, RH | 1 |
| Kuncl, RW | 1 |
| Zorumski, CF | 1 |
| Yamada, KA | 1 |
| Price, MT | 1 |
| Olney, JW | 1 |
| Strahlendorf, JC | 1 |
| Brandon, T | 1 |
| Miles, R | 1 |
| Strahlendorf, HK | 1 |
| Chen, Q | 1 |
| Surmeier, DJ | 1 |
| Reiner, A | 1 |
| Lees, GJ | 1 |
| Leong, W | 1 |
| Moncada, C | 1 |
| Arvin, B | 1 |
| Le Peillet, E | 1 |
| Meldrum, BS | 1 |
1 review available for gyki 52466 and Nerve Degeneration
| Article | Year |
|---|---|
Excitotoxic and post-ischemic neurodegeneration: Involvement of transglutaminases.
Topics: Animals; Benzodiazepines; Brain Ischemia; Calcium; Cells, Cultured; Dizocilpine Maleate; Excitatory | 2004 |
10 other studies available for gyki 52466 and Nerve Degeneration
| Article | Year |
|---|---|
Novel alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptor antagonists of 2,3-benzodiazepine type: chemical synthesis, in vitro characterization, and in vivo prevention of acute neurodegeneration.
Topics: Acute Disease; Animals; Benzodiazepines; Binding, Competitive; Brain Infarction; Cells, Cultured; Di | 2005 |
Administration of a non-NMDA antagonist, GYKI 52466, increases excitotoxic Purkinje cell degeneration caused by ibogaine.
Topics: Animals; Benzodiazepines; Dose-Response Relationship, Drug; Drug Synergism; Excitatory Amino Acid An | 2004 |
p21(WAF1/Cip1) is not involved in kainic acid-induced apoptosis in murine cerebellar granule cells.
Topics: Animals; Apoptosis; Benzodiazepines; Cell Cycle; Cell Cycle Proteins; Cells, Cultured; Cerebellum; C | 2004 |
The effects of AMPA receptor antagonists in models of stroke and neurodegeneration.
Topics: Animals; Animals, Newborn; Anticonvulsants; Benzodiazepines; Brain; Brain Ischemia; Cell Survival; C | 2005 |
Chronic inhibition of superoxide dismutase produces apoptotic death of spinal neurons.
Topics: Acetylcysteine; Amyotrophic Lateral Sclerosis; Animals; Animals, Newborn; Anti-Anxiety Agents; Antio | 1994 |
A benzodiazepine recognition site associated with the non-NMDA glutamate receptor.
Topics: Animals; Anti-Anxiety Agents; Benzodiazepines; Benzothiadiazines; Binding Sites; Binding, Competitiv | 1993 |
AMPA receptor-mediated alterations of intracellular calcium homeostasis in rat cerebellar Purkinje cells in vitro: correlates to dark cell degeneration.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Aniline Compounds; Animals; Anti-Anxiety A | 1998 |
NMDA and non-NMDA receptor-mediated excitotoxicity are potentiated in cultured striatal neurons by prior chronic depolarization.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anti-Anxiety Agents; Benzodiazepi | 1999 |
In vivo, the direct and seizure-induced neuronal cytotoxicity of kainate and AMPA is modified by the non-competitive antagonist, GYKI 52466.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anti-Anxiety Agents; Benzodiazepi | 2001 |
Non-NMDA antagonists protect against kainate more than AMPA toxicity in the rat hippocampus.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anti-Anxiety Agents; Benzodiazepi | 1991 |